Our Pricing

Semaglutide Injection UK - All Doses In Stock Now

Published on: June 03, 2026

Finding a reliable semaglutide injection UK online pharmacy with transparent pricing and all doses in stock can be challenging. At Cured Pharmacy, we provide genuine UK-licensed Wegovy semaglutide injections from £79.00, supported by our GPhC-registered clinical team and superintendent pharmacist Tarun Kumar (GPhC 2233073), with free consultations completed in under three minutes.

How Semaglutide Injection Works for Weight Loss

Semaglutide is a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1, which regulates appetite and food intake. When administered as a weekly subcutaneous injection, semaglutide slows gastric emptying, reduces hunger signals to the brain, and improves glycaemic control [1].

The landmark STEP 1 clinical trial demonstrated that adults using semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Participants also experienced improvements in cardiovascular risk markers, including blood pressure and cholesterol levels.

Unlike oral weight loss treatments, semaglutide injections bypass the digestive system, allowing for more consistent absorption and efficacy. The once-weekly dosing schedule offers convenience compared to daily injectable alternatives, making it easier for patients to maintain adherence to their treatment programme.

Semaglutide Injection UK Dosing Schedule and Titration

The semaglutide injection follows a carefully structured dose escalation protocol to minimise gastrointestinal side effects whilst optimising weight loss outcomes. Treatment typically begins with 0.25mg weekly for four weeks, followed by gradual increases every four weeks [2].

The standard titration schedule progresses from 0.25mg to 0.5mg, then 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly. This gradual approach allows your body to adapt to the medication, significantly reducing the likelihood of nausea and other common side effects that can occur with GLP-1 receptor agonists [2].

Your UK prescriber will determine the appropriate starting dose and escalation timeline based on your individual response, medical history, and tolerability. Some patients may require a slower titration schedule, whilst others may progress more quickly through the dose levels, subject to clinical assessment.

What to Expect During Dose Escalation

During the initial weeks of treatment, most patients experience mild gastrointestinal symptoms such as nausea, which typically diminish as your body adjusts to each new dose level. Staying well-hydrated, eating smaller portions, and avoiding high-fat meals can help manage these temporary effects. Your prescriber will monitor your progress throughout the titration period and adjust the schedule if needed to ensure optimal tolerability whilst working towards your weight loss goals.

Clinical Evidence: STEP Trial Programme Results

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme represents the most comprehensive evaluation of semaglutide for weight management, involving over 4,500 participants across multiple international studies [1][3].

In STEP 1, 69% of participants achieved at least 10% body weight reduction, and 50% achieved at least 15% reduction with semaglutide 2.4mg weekly, compared to just 12% and 5% respectively in the placebo group [1]. These results exceeded outcomes seen with previous weight loss medications and established semaglutide as one of the most effective pharmacological treatments available.

The STEP 2 trial specifically examined semaglutide in adults with type 2 diabetes, demonstrating an average weight loss of 9.6% alongside improvements in HbA1c levels [3]. STEP 3 combined semaglutide with intensive behavioural therapy, achieving average weight reductions of 16% over 68 weeks, whilst STEP 4 evaluated weight maintenance after initial loss, showing sustained results over extended treatment periods.

Long-Term Safety and Cardiovascular Benefits

Beyond weight loss, the STEP trials documented significant improvements in cardiovascular risk factors, including reductions in systolic blood pressure, improvements in lipid profiles, and decreased inflammatory markers [3]. The SELECT cardiovascular outcomes trial further demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by 20% in adults with established cardiovascular disease, independent of weight loss effects [4]. These findings support the broader health benefits of semaglutide treatment beyond body weight reduction alone.

Semaglutide vs Other Weight Loss Injections

The UK weight loss injection market now includes several GLP-1 receptor agonists and dual-action medications, each with distinct efficacy profiles and dosing schedules. Understanding these differences helps you and your prescriber select the most appropriate treatment for your individual circumstances.

Semaglutide (marketed as Wegovy for weight loss) offers once-weekly dosing and demonstrated superior weight loss compared to liraglutide in head-to-head trials. Tirzepatide, a newer dual GIP/GLP-1 receptor agonist, has shown even greater average weight reductions in clinical trials, though both medications remain effective options depending on individual patient factors and tolerability [1][5].

Liraglutide requires daily injections and typically produces more modest weight loss compared to weekly semaglutide, though it remains a valuable option for patients who prefer daily dosing or have specific contraindications to other treatments. All injectable weight loss medications require prescription and ongoing clinical supervision by UK-registered prescribers.

Who Can Use Semaglutide Injection in the UK

Semaglutide injection is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [2]. Your prescriber will calculate your BMI and assess your medical history during the online consultation.

Certain medical conditions may preclude semaglutide use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy requiring active treatment. Pregnant or breastfeeding women should not use semaglutide, and treatment should be discontinued at least two months before planned conception [2].

Your UK prescriber will review your complete medical history, current medications, and treatment goals to determine whether semaglutide is appropriate and safe for you. This clinical assessment is mandatory for all prescription weight loss medications and ensures you receive personalised care tailored to your individual health profile.

Contraindications and Precautions

Patients with a history of pancreatitis should discuss potential risks with their prescriber, as GLP-1 receptor agonists have been associated with pancreatitis in rare cases. Those taking other medications that affect blood sugar levels, including insulin or sulfonylureas, may require dose adjustments to prevent hypoglycaemia. Your prescriber will evaluate all potential drug interactions and medical contraindications before approving your semaglutide prescription.

How to Order Semaglutide Injection UK from Cured Pharmacy

Ordering your semaglutide injection from Cured Pharmacy is straightforward and completed entirely online. Begin by clicking 'Start Assessment' on our Wegovy product page, where you'll complete a brief medical questionnaire covering your health history, current medications, weight loss goals, and any relevant medical conditions.

Our UK-registered prescribers review every consultation individually, typically within hours during business days. If semaglutide is deemed appropriate and safe for you, your prescription will be approved and sent directly to our GPhC-registered pharmacy (registration number 9012511) for dispensing. We stock all semaglutide doses, ensuring your treatment begins without delay.

Your medication is dispatched in discreet, unmarked packaging via tracked courier service. We provide transparent upfront pricing before you complete your consultation, so you'll know the exact cost of your treatment with no hidden fees. Our clinical team remains available throughout your treatment journey to answer questions and provide ongoing support as you progress through your weight loss programme.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. [accessed 13 August 2026]
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Semaglutide injection is a prescription-only medicine and should only be used under the supervision of a healthcare professional. Individual results may vary, and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to treatment. The clinical trial data referenced represents average outcomes in controlled study conditions and may not reflect results in all patients.